Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases

Cancer Letters

Volumn 264, Issue 2, 2008, Pages 201-208

  Hosny, Gihan ^a   Farahat, Nahla ^b   Tayel, Hanan ^b   Hainaut, Pierre ^c  

^a ALEXANDRIA UNIVERSITY   (Egypt)

^b ALEXANDRIA UNIVERSITY   (Egypt)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Catenin; Egypt; HCC; Hepatocellular carcinoma; Ser 249 TP53; TP53

Indexed keywords

AFLATOXIN; BETA CATENIN; DNA; SERINE;

ADULT; AGED; ARTICLE; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; CTNNB1 GENE; EGYPT; FEMALE; GENE; GENE MUTATION; GENE SEQUENCE; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TP53 GENE;

ADULT; AFLATOXINS; AGED; BASE SEQUENCE; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CHRONIC DISEASE; DNA; DNA MUTATIONAL ANALYSIS; EGYPT; FEMALE; GENES, P53; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; POISONS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 43049168956     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.01.031     Document Type: Article

References (28)

1. Pisani P., Parkin D.M., Bray F., and Ferlay J. Estimates of the worldwide mortality from 25 cancers. Int. J. Cancer 83 (1999) 18-29. http://www.who.int/mediacentre/releases/2003/pr27/en/ WHO Report (2003) on global cancer rates http://www.who.int/mediacentre/releases/2003/pr27/en/
2. IARC, Monographs on evaluation of carcinogenic risks to humans, International Agency for Research on Cancer, vol. 82, 2002, Lyon, France.
3. Kirk G.D., Lesi O.A., Mendy M., Akano A.O., Sam O., Goedert J.J., Hainaut P., Hall A.J., Whittle H., and Montesano R. The Gambia liver cancer study: infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology 39 (2004) 211-219
4. ser TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene 24 (2005) 5858-5867
5. Pisani P., Parkin D.M., Munoz N., and Ferlay J. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol. Biomarkers Prev. 6 (1997) 387-400
6. Zekri A.R., Bahnassy A.A., Madbouly M.S., Asaad N.Y., El-Shehaby A.M., and Alam-Eldin H.M. p53 mutation in HCV-genotype-4 associated hepatocellular carcinoma in Egyptian patients. J. Egyptian Nat. Cancer Inst. 18 1 (2006) 17-29
7. Bahnassi A.A., El-Houssini S., Mokhtar N.M., Khaled H.M., El-Mishad A.M., and Zekri A.R. Correlation between HCV-NS3p and p53, p21waf, MDM2, p21, Ras, and C-erb2 in HCV associated hepatocellular carcinoma and adjacent pericarcinomatous foci. J. Egyptian Nat. Cancer Inst. 14 1 (2002) 75-85
8. Wang X.W., Hussain S.P., Huo T.I., Wu C.G., Forgues M., Hofseth L.J., Brechot C., and Harris C.C. Molecular pathogenesis of human hepatocellular carcinoma. Toxicology 181-182 (2002) 43-47
9. Hainaut P., and Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 77 (2000) 81-137
10. Anker P., Mulcahy H., Chen X.Q., and Stroun M. Detection of circulating tumor DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev. 18 (1999) 65-73
11. Anker P., Mulcahy H., and Stroun M. Circulating DNA in plasma or serum. Int. J. Cancer 103 (2003) 149-152
12. Gormally E., Caboux E., Vineis P., and Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutation Res. 635 (2007) 105-117
13. Gormally E., Hainaut P., Caboux E., et al. Int. J. Cancer 111 (2004) 746-749
14. Szymanska K., Lesi O.A., Kirk G.D., Sam O., Taniere P., Scoazec J.-Y., Mendy M., Friesen M.D., Whittle H., Montesano R., and Hainaut P. Ser-249 TP53 mutation in tumour and plasma DNA of Hepatocellular carcinoma from a high incidence area in the Gambia, West Africa. Int. J. Cancer 110 (2004) 374-379
15. E. Le Roux, Pattern of HBV/HCV infection and TP53/beta-catenin mutations in HCC cases from Thailand, Ph.D. Thesis, Director, Hainaut P, IARC, Lyon, France, 2007.
16. Staib F., Hussain S.P., Hofseth L.J., Wang X.W., and Harris C.C. TP53 and liver carcinogenesis. Hum. Mutat. Mar. 21 3 (2003) 201-216
17. Bressac B., Kew M., Wands J., and Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature Apr 4 350 6317 (1991) 429-431
18. Hollstein M.C., Sidransky D., Vogelstein B., and Harris C.C. p53 mutations in human cancers. Science 253 (1991) 49-53
19. Hollstein M.C., Wild C.P., Bleicher F., Chutimataewin S., Harris C.C., Srivatanakul P., and Montesano R. p53 mutations and aflatoxin B1 exposure in hepatocellular carcinoma patients from Thailand. Int. J. Cancer 53 (1993) 51-55
20. Ding X., Park Y.N., Taltavull T.C., et al. Geographic characterization of hepatitis virus infections, genotyping of hepatitis B virus, and p53 mutation in hepatocellular carcinoma analyzed by in situ detection of viral genomes from carcinoma tissues: comparison among six different countries. Jpn. J. Infect. Dis. 56 1 (2003) 12-18
21. Oda T., Tsuda H., Scarpa A., Sakamoto M., and Hirohashi S. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res. Nov. 15 22 (1992) 6358-6364
22. Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., and Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 28 6 (2007) 622-629
23. Gormally E., Vineis P., Matullo G., et al. TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. Cancer Res. 66 13 (2006) 6871-6876
24. Ziegler A., Zangemeister-Wittke U., and Stahel R.A. Circulating DNA: a new diagnostic gold mine?. Cancer Treat. Rev. 28 (2002) 255-271
25. Jackson P.E., kuang S.Y., Wang J.B., et al. Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients. Carcinogenesis 24 (2003) 1657-1663
26. Sheen I.S., Jen K.S., and Wu J.Y. Is p53 mutation an indicator of the biological behaviors of recurrence of HCC. W. J. Gastroenterol. 6 (2003) 1202-1207
27. Devereux T.R., Stern M.C., Flake G.P., Yu M.C., Zhang Z.-Q., London S.J., and Taylor J.A. CTNNB1 mutations and β-catenin protein accumulation in human hepatocellular carcinomas associated with high exposure to aflatoxin B1. Mol. Carcinogenesis 31 (2001) 68-73
28. Wong C.M., Fan S.T., and Ng I.O.L. β-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 92 1 (2001) 136-145